Coverage
-
March 10, 2015
A California federal judge on Monday dismissed a proposed shareholder class action accusing experimental drug developer Vical Inc. of misleading investors about its cancer drug, describing the complaint as an attempt to punish a corporation and its officers for expressing incorrect opinions.
1 other articles on this case.
View all »